Table 1.

Patient characteristics and mutational information

Clinical information	Total (N=18)	Lung (N=12)	Non-lung (N=6)
Median age (range)	53 (28–80)	52 (28–70)	62 (49–80)
Sex
Male	7 (38.9%)	4 (33.3%)	3 (50%)
Female	11 (61.1%)	8 (66.7%)	3 (50%)
Stage
IV	9 (50%)	7 (58.3%)	2 (33.3%)
Unknown	9 (50%)	5 (41.7%)	4 (66.7%)
Treatment
TKI-involved	10 (55.6%)	9 (75%)	1 (16.7%)
TKI-exclusive	4 (22.2%)	2 (16.7%)	2 (33.3%)
Unknown	4 (22.2%)	1 (8.3%)	3 (50%)
Mutation type
Ex16 deletion	13 (72.2%)*	8 (66.7%)*	5 (83.3%)
Splice site deletion	2 (11.1%)	1 (8.3%)	1 (16.7%)
Splice site point mutation	4 (22.2%)*	4 (33.3%)*	0

*One patient harboured both Ex16 deletion and splice site point mutation.

Ex16, exon 16; TKI, tyrosine kinase inhibitor.